文献速递急性肾损伤肾移植

克服急性肾损伤转化壁垒:NIDDK研讨会报告

Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-03-09

美国NIDDK于2015年2月召开研讨会,采用反向转化医学方法,为移植肾功能延迟恢复、AKI一级预防和AKI治疗设计可行的2期概念验证临床试验,并识别能复制患者病理生理的临床前动物模型。与会者指出人类AKI知识、临床前模型病理生理理解及分子靶点保真度存在显著缺口,并提出新路径。

要点

  • 目前尚无药物能预防或治疗人类AKI。
  • 研讨会采用反向转化医学方法设计2期概念验证试验。
  • 临床前模型与人类AKI病理生理及靶点保真度存在显著缺口。

核心结论

  • 尽管临床试验方法学和啮齿类AKI病理生理认识有进展,目前仍无药物可用于人类AKI的预防或治疗。
  • 研讨会识别了人类AKI知识、临床前模型病理生理理解及分子靶点保真度的显著缺口,并定义了新路径。

研究设计与样本

  • 美国国立糖尿病、消化和肾脏疾病研究所于2015年2月10-12日召开「AKI Outcomes: Overcoming Barriers in AKI」研讨会。
  • 研讨会采用反向转化医学方法,分组设计移植肾功能延迟恢复、AKI一级预防和AKI治疗的2期概念验证临床试验,并识别匹配的临床前动物模型。

主要发现

  • 研讨会分组先设计针对移植肾功能延迟恢复、AKI预防和治疗的可行的2期概念验证临床试验,包含主要和次要终点。
  • 分组随后识别能复制2期概念验证患者人群病理生理的临床前动物模型。
  • 分组发现人类AKI知识、临床前模型病理生理理解及临床前评估的细胞和分子靶点保真度存在显著缺口。

临床怎么用

  • 研讨会建议以反向转化医学方法设计AKI 2期概念验证临床试验,并匹配能复制患者病理生理的临床前模型。

局限性

  • 原文未报告研讨会具体推荐条款、数值阈值或样本量等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AKI is a complex clinical condition associated with high mortality, morbidity, and health care costs. Despite improvements in methodology and design of clinical trials, and advances in understanding the underlying pathophysiology of rodent AKI, no pharmacologic agent exists for the prevention or treatment of AKI in humans. To address the barriers that affect successful clinical translation of drug targets identified and validated in preclinical animal models of AKI in this patient population, the National Institute of Diabetes and Digestive and Kidney Diseases convened the "AKI Outcomes: Overcoming Barriers in AKI" workshop on February 10-12, 2015. The workshop used a reverse translational medicine approach to identify steps necessary to achieve clinical success. During the workshop, breakout groups were charged first to design feasible, phase 2, proof-of-concept clinical trials for delayed transplant graft function, prevention of AKI (primary prevention), and treatment of AKI (secondary prevention and recovery). Breakout groups then were responsible for identification of preclinical animal models that would replicate the pathophysiology of the phase 2 proof-of-concept patient population, including primary and secondary end points. Breakout groups identified considerable gaps in knowledge regarding human AKI, our understanding of the pathophysiology of AKI in preclinical animal models, and the fidelity of cellular and molecular targets that have been evaluated preclinically to provide information regarding human AKI of various etiologies. The workshop concluded with attendees defining a new path forward to a better understanding of the etiology, pathology, and pathophysiology of human AKI.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zuk A, Palevsky PM, Fried L, et al. Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop. Clin J Am Soc Nephrol. 2018. PMID: 29523680. doi:10.2215/CJN.06820617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。